Company Filing History:
1 out of 45 
1 out of 4 
1 out of 3 Years Active: 2025
Title: Helena Montanuy Escribano: Innovator in Cancer Treatment
Introduction
Helena Montanuy Escribano is a prominent inventor based in Barcelona, Spain. She has made significant contributions to the field of cancer treatment through her innovative research and patenting efforts. Her work focuses on the therapeutic use of afatinib, a drug that has shown promise in treating cancers associated with DNA damage repair defects.
Latest Patents
Helena holds a patent for the "Therapeutic use of afatinib in cancer." This invention provides afatinib or a pharmaceutically acceptable salt thereof for use in the treatment and/or prevention of cancer in patients suffering from diseases caused by defects in DNA damage repair mechanisms. Remarkably, when afatinib was administered to Fanconi Anemia (FA) cells, it demonstrated a therapeutic anti-cancer effect without any toxic side effects on DNA. This breakthrough has the potential to change the landscape of cancer treatment.
Career Highlights
Throughout her career, Helena has worked with esteemed institutions such as Universitat Autònoma De Barcelona and the Consorcio Centro De Investigación Biomédica En Red. Her research has not only advanced scientific understanding but has also paved the way for new therapeutic strategies in oncology.
Collaborations
Helena has collaborated with notable colleagues, including Jordi Surrallés Calonge and Jordi Minguillón Pedreño. These partnerships have enriched her research and contributed to the success of her innovative projects.
Conclusion
Helena Montanuy Escribano is a trailblazer in the field of cancer treatment, with her patent on afatinib showcasing her commitment to advancing medical science. Her work exemplifies the impact of innovation in addressing critical health challenges.